59% upside: LEU + $2.7B nuclear fuel regime shift

Energy bill came this month. Up again. Meanwhile the US is still wiring $1 billion a year to Russia for enriched uranium. There's a company in Piketon, Ohio that's the only American answer to that problem. Nobody's talking about it.

Centrus Energy (NYSE: LEU) is trading near a 52-week low. The consensus analyst price target sits at $274 against a current price around $172 — implying roughly 60% upside before you factor in any re-rating. Eleven analysts have Buy ratings. Zero have Sell ratings. The stock is down 63% from its 52-week high of $464. That gap doesn't mean the thesis is broken. It means the market is pricing execution risk on a build-out rather than pricing the asset itself.

What Centrus actually is: the only company in the United States with a Nuclear Regulatory Commission-approved facility to produce HALEU, the high-assay fuel that powers next-generation small modular reactors. It's also one of only two entities licensed to produce standard commercial low-enriched uranium domestically. That's not a competitive moat — that's a government-certified monopoly on a critical input.

The backlog makes the case more concretely. Total contracted backlog stands at $3.8 billion extending through 2040, including $2.3 billion in commercial LEU commitments. In January 2026, the DOE awarded Centrus's American Centrifuge Operating subsidiary a $900 million task order to expand its Piketon, Ohio facility for commercial-scale HALEU production. That's part of a broader $2.7 billion federal push to rebuild domestic enrichment entirely.

The bear case is timing. Centrus projects the first new production cascade will be operational 42 months after funds and commitments are fully secured. That's a long runway, and near-term earnings won't look dramatic. Q1 2026 revenue came in at $76.7 million — solid, but not a headline number. The company has $1.9 billion in cash, which means it won't run out of runway while it builds. For patient investors, buying a licensed nuclear fuel monopoly at a 63% drawdown from its high is the kind of setup this newsletter exists to find.

Most uranium investors are still looking at miners. That's not where the asymmetry is. The HALEU market is projected to grow from $260 million in 2026 to $6.2 billion by 2030 — a 23x expansion in four years driven by advanced reactor deployments. Centrus is the only US-owned operator with licensed HALEU production today. It's already exploring a joint venture with Oklo focused on HALEU deconversion services, adding another revenue layer beyond simple enrichment. The enrichment bottleneck is real and structural. The DOE plans to back the first 5 to 10 new US reactors with federal loans — each one needing a domestic fuel supply that currently doesn't exist at scale. Centrus is it.

That's where long-term uranium contract prices have climbed — the highest level since 2008. Spot price sits around $86. Bank of America published a bullish note in March calling for $135 per pound by 2027. If they're right, every unhedged pound of uranium sold by producers next year gets 57% more valuable overnight. Cameco's locked most of its production into long-term contracts at $85 to $89 per pound, which sounds defensive until you realise they're also protecting against a downside scenario that BofA doesn't see coming.

Everyone buying uranium exposure defaults to Cameco (CCJ). It's the obvious name, well covered, institutionally owned, and priced accordingly. Cameco's Q1 2026 net income rose 87% to $93.8 million, which is genuinely impressive. But Cameco is a miner. When uranium prices move, Cameco moves. When they don't, neither does Cameco.

Centrus is a different animal. It earns from enrichment services, not spot prices — so it benefits from the fuel cycle tightening regardless of whether the commodity price spikes this quarter or next year. The World Nuclear Association projects uranium demand rising more than 40% by 2035, and that demand has to get enriched before it reaches a reactor. The enrichment bottleneck is arguably more durable than the mining bottleneck, and Centrus owns it domestically. The trade on Cameco has already been made. The trade on LEU hasn't.

The EUAD ETF — the purest listed play on European rearmament — is down roughly 4% year to date in 2026 after climbing 75% through mid-2025. The Stoxx Europe Aerospace and Defence index is down 1.2% year to date, trailing the broader Stoxx 600's 4.8% gain. Markets are treating this as a sector cooling off. The underlying numbers don't agree.

At the NATO Summit in The Hague, European allies committed to raise core defence spending to 3.5% of GDP by 2035, with an additional 1.5% earmarked for broader security investments — total 5% of GDP. Germany's 2026 federal budget earmarks €108 billion for defence alone, a 25% year-on-year increase, and the country is targeting the 3.5% threshold by 2029 — six years ahead of NATO's own deadline. That's not a sentiment trade. That's contracted procurement.

The names worth watching aren't the ones that already ran 400% (Rheinmetall). Goldman projects Europe's rearmament will add 0.9% to global copper demand, 1.3% to nickel, and lift the region's overall industrial metals demand by 6% by 2027. The indirect plays — electronic warfare specialists like Hensoldt, drone enablers, and the metals sitting inside every weapons system — are where the market hasn't fully re-priced yet. The spending is locked in. The supply chain hasn't caught up.

Cameco Q1 2026 earnings breakdown Net income up 87%, $230M in long-term contracts added. The miner's quarter, properly analysed. Carbon Credits

DOE $2.7B enrichment awards announcement The three companies getting funded, the milestone structure, and what $900M means for Centrus timelines. US Department of Energy

Centrus Q1 2026 earnings release Revenue, raised guidance, and the Oklo joint-venture announcement in full. PR Newswire

Uranium spot price outlook — BofA $135 call The bull note that moved the sector in April, with the supply-deficit maths behind it. CNBC

European defence: five industries benefiting from rearmament Copper, drones, cyber, semiconductors, and the primes — ranked by exposure and revenue visibility. Euronews

Janus Henderson: Europe's rearmament magnitude underappreciated Portfolio managers O'Malley and McManus on why markets are still pricing this wrong. Janus Henderson

Re-reading the original DOE enrichment award documents from January. The language about ending Russian uranium dependence reads like something written in genuine alarm. Somebody in Washington understood the problem before the market did.